Browsing Tag
cardiovascular biotech
2 posts
What the RIDGE-1 interim results reveal about the future of cardiac gene therapy in ARVC
Could TN-401 reshape inherited heart disease treatment? Explore what Tenaya Therapeutics, Inc.’s RIDGE-1 data means for cardiac gene therapy.
CVKD expands clinical pipeline with acquisition of VLX-1005, a Phase 2 12-LOX inhibitor for HIT patients
Discover how Cadrenal Therapeutics’ acquisition of VLX-1005 could reshape treatment options for heparin-induced thrombocytopenia and strengthen its anticoagulation pipeline.